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Abstract 
Several Neisseria gonorrhoeae (NG) nucleic acid amplification tests (NAATs) exist with high 
sensitivity. However, specificity of NG NAAT testing may be suboptimal, particularly in extra-
genital biospecimens.  Consequently, confirmation with a second NAAT is common, 
although represents a burden on resources. Furthermore, the rationale for confirmation is 
contentious. 
The objective of this work was to assess NG confirmation in over 13,000 NG screen-positive 
samples representing various biospecimens and three separate screening assays: the Abbott 
Real Abbott RealTime CT/NG (Abbott Molecular Inc., Des Plaines, IL), the Cobas CT/NG test 
(Roche Diagnostics, Indianapolis, IN) and the BD ProbeTec ET CT/GC Amplified DNA assay 
(Becton Dickinson and Company, Sparks, MD). Factors predictive of confirmation were 
determined via logistic regression involving: sex, year, whether the samples was formally 
validated and sample site. 
Level of confirmation varied according to screening assay (96.2%, 86.0% and 73.9%) for the 
Abbott, Roche and BD test respectively in sample types formally included according to 
manufacturers instructions (i.e.-validated). Sex did not affect confirmation for 2/3 assays 
and the likelihood of confirmation of samples not formally included in manufacturer 
instructions (ie non validated) was 89.1%, 82.1% and 59.2% for the Abbott Roche and BD 
test respectively. Rectal swabs, which are non validated samples, confirmed in 91.5%, 90.1% 
and 87.4% of samples initially tested with the respective assays  
 The requirement to confirm NG in validated samples is not required for all NAATs although 
initial, assay-specific evaluation is justified given observed variability. Rectal samples 
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represent robust biospecimens for NG NAAT testing and do not require confirmation when 
screened with the assays described. 
Introduction 
The management of Neisseria gonorrhoeae (NG) infection represents an increasing and 
significant clinical burden, in various settings including the UK. ln Scotland in 2017 there 
were 2610 episodes of gonorrhoea, in comparison with only 1073 cases in 2008 (1). Similar 
observations of an increase over the last decade have also been noted in England. (2) 
Quantifying the magnitude of the increase as a result of changed sexual behaviours and/or 
shortfalls in management approaches is confounded by variability in indications for testing 
and the increased use of highly sensitive nucleic acid amplification tests (NAAT). Consistency 
of recommendations for testing-practice and application of robust NAATs can support the 
more accurate measurement of genuine trends. Certainly, NAAT rather than culture of NG is 
recommended as a first line test and an increasing diversity of molecular tests exists. Assay-
driven influences in NAAT confirmation of NG have been reported including in a recent UK 
study where 27% of samples from females did not confirm with a second line test (3). These 
data reconcile with those from a study by Vyth et al (2016) who reported that assay-choice 
significantly influenced the likelihood of culture confirmation (4).  
Guidance for the application of NG NAATs is available with the purpose of harmonising 
approach to support practically achievable, meaningful and technically-robust testing.  Such 
guidance includes that from Public Health England (PHE) which recommends confirmatory 
testing of all extra-genital samples, with an assay that targets a different sequence from the 
initial assay in order to enhance specificity (5). The same guidelines stipulate that 
“laboratories should only issue positive test results that are confirmed by supplementary 
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testing or, for genital samples, where the positive predictive value (PPV) of the initial NAAT 
has been validated in the local laboratory as being ≥90%”. The British Association for Sexual 
Health and HIV (BASHH, 2011) offer similar advice on confirmatory testing including the 
requirement for confirmation of extra-genital samples (6). Guidance on confirmatory testing 
has also been issued by the Centre for Disease Control CDC (2014) which stipulate that 
repeat testing of NAAT-positive genital tract specimens is not recommended (if the 
screening assay is FDA approved) “because the practice does not improve the positive 
predictive value of the test” (7). For extra-genital sites the guidance indicates that in-house 
validation to CLIA standards is sufficient.  
This all said, how closely real-life practice follows guidance is not documented. Confirmatory 
testing of validated genital samples occurs and this is not exclusive to those laboratories 
where the initial NAAT has been confirmed to have a PPV of <90%. Furthermore, as 
described, NAATs continue to evolve and improve; whether confirmatory testing, including 
that associated with samples from extra-genital sites is needed requires evidence-based 
assessment.  This consideration is made relevant by the fact that confirmatory testing does 
not represent a trivial resource implication for the laboratory. 
The evolution of NG NAATs, the increased diversity of biospecimens tested in service 
laboratories and the disconnectedness and vintage of the guidelines justifies further 
detailed interrogation of the value of NG NAAT confirmation in large, population based, 
data series. The objective of the present work was to determine the level of NG 
confirmation in over 13,000 samples representing various biospecimen types from males 
and females and sent to a reference laboratory facility for routine confirmation via in-house 
PCR.  Variables which influenced confirmation were subsequently detemined.   
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Material and Methods 
Context and dimensions of sample 
Currently, NG testing in Scotland is recommended only for groups where the prevalence is 
likely to be greater or equal to 1%, in line with national guidelines. The Scottish Bacterial STI 
reference laboratory provides a centralised, national service of NG NAAT confirmation for 
Scottish Health Boards (8). The timeframe under study relates to samples received between 
Jan 2009 to June 2016.   
Confirmation testing 
 The reference, confirmatory test was based on an in house approach which involved two 
multiplex real-time PCR methods, each incorporating an extraction inhibition control 
(phocine herpes virus-1) and a target specific for N. gonorrhoeae (porA and 16S rRNA 
genes). Samples (urine or swab eluate) were concentrated by centrifugation of 1 ml at 
20,000 g for 5 min, then discarding 800 µl supernatant. Extraction of the samples was by 
NucliSENS easyMAG (Biomerieux, Marcy-l’Etoile, France) automated extractor using the 
Generic 2.0.1 protocol, adding 200 µl and eluting in 100 µl. In the event of inhibition the 
Qiagen QIAamp DNA Mini kit was utilised, again with the addition of 200 µl sample and a 
final elution volume of 100 µl. 
 
The first line assay targeted the porA gene (Whiley, 2005), with a limit of detection of 
around 10 copies/ml in swab eluate and 100 c/ml in urine samples (9). The second line assay 
targeted the 16S rRNA gene to detect porA-negative strains. This method was developed in-
house. Although the primers were found to bind to other non-gonococcal Neisseria species, 
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the probe was specific to N. gonorrhoeae. Therefore this assay may lead to false-negative 
results where non-gonococcal Neisseria are present, such as the pharynx   Note that no 
further adjudication with .an additional assay was performed if there was discordance 
between the screening assay and the reference test. 
 
Measuring agreement of screening vs confirmation test and identification of significant 
predictors of confirmation. 
Level of confirmation was performed according to screening assay, specimen type 
(individual anatomical site), sex and the year of screening test through comparison with the 
reference laboratory confirmation test. Confirmation was also assessed according to 
whether a sample was considered validated (urine or genital swab) or non validated (all 
other samples) by the manufacturer of the screening test.  
To determine what factors were predictive of confirmation for each screening assay 
individually, a logistic regression was performed using sex (male/female), whether the 
samples was validated (yes/no) and specific sample site/type. Year the samples was 
submitted (2009-2016 - treated as a continuous variable) was also included to serve as a 
proxy for the potential influence of assay version-change over time which was not available 
in the data set. Additionally, arguably sample year provides potential insight into the 
significance other factors within general lab testing environment that may have changed 
over time. Where any variables were found to not to be statistically significant they were 
sequentially removed to generate a final model containing only those variables which 
reached statistical significance at the 5% level. For the purpose of the regression, any 
sample with unknown sex and/or whether unvalidated vs validated status could not be 
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confirmed was removed. The small number eye swabs (n=11) led to their removal for the 
regression analysis. 
Results 
Description of samples 
Data were excluded if the technology of the sender was undefined, or if the screening test 
was NG negative. A total of 13803 specimens were subsequently included in the analysis;  
69.7% were from males and 54.9% of samples were manufacturer-validated. The most 
common screening assay accounted for 73.5% of samples (n=10,139) and was the Abbott 
RealTime CT/NG assay (Abbott Laboratories, Abbott Park, IL, USA) compared to 13.2% 
(n=1824) and 13.3% (n=1841) samples screened by the Cobas 4800 (Roche Diagnostics, 
Pleasanton, CA, USA), and BD ProbeTec™ ET GC Amplified DNA Assay (Franklin Lakes, NJ, 
USA) respectively. One sample was tested with both platforms, Abbott and Roche. Key 
variables that relate to the data set under assessment are presented in Table 1. 
 
Overall agreement between screening vs confirmatory assay 
Overall, the confirmatory assay was positive in 12,184/13803 samples 88.3%; (95% CI: 87.7 – 
88.8). Overall agreement was 93.1%; (95% CI: 92.6 – 93.6) with the Abbott assay, 84.0% 
(95% CI: 82.2 – 85.6) with the Roche assay and 65.9% (95% CI: 63.7 – 68.1) with the BD assay 
(Table 2).  
Table 3 shows level of confirmation with the screening and confirmatory assay according to 
sex, sampling year, validation status of sample and specific sample type, according to each 
assay.  A small effect on confirmation according to sampling year was observed; with a 
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reduced likelihood for confirmation over time/sampling year. Confirmation according to 
gender was 93.6% for female samples vs 92.9% in male samples for the Abbott assay. 
Respective values for the Roche assay were 80.5% and 85.5% for female and male samples. 
Finally for the BD assay 58% of female samples confirmed vs 70.1% of male samples.    
As expected specimen type/site and validation status did influence likelihood of 
confirmation. For formally validated (by the manufacturer) specimens, confirmation was 
evident in 96.2%; (95% CI: 95.7 – 96.6), 86.0% (95% CI: 83.7 – 88.1) and 73.9% (95% CI: 70.8 
– 76.7) of specimens initially tested with the Abbott, Roche and BD assays respectively. In 
relation to unvalidated specimens 89.1%; (95% CI: 88.1 – 89.9), 82.1%; (95% CI: 79.4 – 84.4) 
and 59.2% (95% CI: 56.0 – 62.2) confirmed with the Abbott, Roche and BD test respectively. 
The most common unvalidated specimens were throat swabs (n=2817) and rectal swabs 
(n=2207). Confirmation of throat swabs was evident in 87.1%; (95% CI: 85.6 – 88.4), 78.1%; 
(95% CI: 74.4 – 81.3) and 49.5%; (95% CI 45.8 – 53.2) of specimens tested with the Abbott, 
Roche and BD assays respectively. Equivalent figures for confirmation of rectal swabs 
according to assay were higher at 91.5%; (95% CI: 90.2 – 92.7), 90.1%; (95% CI: 86.1 – 93.0) 
and 87.4%; (95% CI: 82.7 – 91.0) according to respective assay; similar to confirmation levels 
associated with validated biospecimens.  
The sample type, least likely to confirm was an eye swab at 54.5%; (95% CI: 28.0 – 78.7) with 
the caveat that only 11 were submitted for confirmation. 
 
Which factors are significantly associated with confirmation? 
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Variables that were identified as significant are included in Table 4. Factors influencing 
confirmation of the Abbott assay were that samples from females were more likely to 
confirm. Additionally a small year on year reduction in likelihood of confirmation was 
observed. Finally, cervical, rectal, urethral and urine samples were all more likely to confirm 
compared to vulval samples.  
The only factor that was associated with confirmation with the Roche assay was sample 
year, however 2009 (which related to only 24 samples of which only one confirmed) may 
represent an anomaly and partially account for this observation. A greater number of 
factors were found to significantly affect confirmation of the BD assay, namely that female 
samples were less likely to confirm.  With respect to specific sample types, cervical samples 
were less likely to confirm compared to vulval samples throat samples were less likely to 
confirm compated to vulval samples and urethral samples were more likely to confirm 
compared to vulval samples. Additionally a small year on year reduction in likelihood of 
confirmation was observed. 
 
Discussion 
The increase in NG infection and the implications of this necessitate swift and accurate 
diagnosis to support and inform both epidemiological assessment and crucially, appropriate 
clinical support and management. The need for confirmation requires review so that 
resources can be used equitably and efficiently.  In this evaluation we observed that the two 
most commonly applied first line tests for NG in Scotland showed high concordance with a 
secondary reference test performed in a centralised reference laboratory and exceeded 
(Abbott) or approached (Roche) 90%. This puts into question the additional value that is 
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gained via confirmation of samples initially tested with these assays particularly with respect 
to validated samples (10,11) 
Of interest confirmation of rectal swabs (the second most common non-validated specimen 
received), exceeded 90% for the Roche and Abbott assay and was 87% for the BD, which 
was actually higher than confirmation associated with certain validated samples for the 
latter assay. These data are consistent with those in an earlier study by Perry et al (2014) 
who concluded that rectal NG positives generated by the Roche 4800 assay did not require 
confirmation when compared to an opa/pap duplex assay (12). While the conclusions of 
Perry and colleagues were on the basis of less than 100 samples they are nevertheless 
validated in the present study where over 2000 rectal NG screen positive samples were 
assessed.  Abandoning confirmation of screen positive rectal samples may represent a 
significant efficiency; in Scotland the rise in NG in men, is thought to be largely driven by 
men who have sex with men (MSM) and in 2017, 37% of episodes in men were diagnosed 
from a rectal swab positive for gonorrhoea (1). The most common non validated sample 
type; the throat swab, was associated with a lower level of confirmation overall compared 
to rectal swabs, although the level of confirmation varied considerably depending on assay 
and  ranged from ~50% (BD Assay)  to ~90%  (Abbott Assay).   The greater likelihood of 
cross-reacting non gonorrhoeae Neisseria species in the throat (compared to other 
anatomical sites) explains this issue of analytical specificity and these observations are 
consistent with the information in the BD assay product insert. Consequently, expectations 
on likelihood of confirmation of throat samples the should be managed and the type of 
screening assay taken into account. 
 
 
11 
 
Certainly the present work has demonstrated that assay type can drive discordance, so 
specific evaluation of other and novel assays is warranted when considering whether 
confirmation is required. This said, it would appear that the current state of the art of 
commercial NG assays is promising. A recent article by Causer et al (2018) showed a 
reassuring level of concordance between point of care (POC) testing with the Xpert CT/NG 
assay (Cepheid, Wooburn Gree, UK) vs standard of care. In this study, overall concordance 
for NG detection was 99.9% with positive concordance of 100.0% and negative concordance 
of 99.9% (13). Clearly, POC testing does not rely on confirmation of the result at a reference 
laboratory and growing interest in POC is evident in new technologies and quality processes 
to support this approach (14 - 16). 
There are limitations to the study, as indicated, we accept that there are an increasing 
number of NG assays available and in the present study, we evaluated only three platforms.  
Furthermore, the most common screening assay applied was the Abbott test by some 
margin meaning that as a function of its larger sample size, smaller differences (in 
confirmation) were more likely to be significant when compared to the other two assays.  In 
addition we accept that any reference/confirmatory test is not itself impervious to error.  
However the strengths of the study are the large overall denominator which allowed 
assessment of concordance according to several variables including specific sample 
site/biospecimen type - and the fact that the demographic was population-based given that 
samples were sent from across Scotland as part of a routinely offered service.  
To conclude, the level of confirmation with NG screening assays and an in house reference 
assay was high and exceeded or approached 90% for the two most commonly used assays in 
Scotland in validated samples. The rationale for confirmatory testing of validated samples 
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tested by the Abbott and Roche assays is therefore not supported.  In addition rectal swabs 
appear to constitute robust bio-specimens for NG testing and confirmatory testing may not 
be justified. 
 
 Variable  Description 
 
N  
(n=13803) 
% 
Sex Male 9609/13780 69.7 
Sample year 2009 284 2.1 
2010 1417 10.3 
2011 1896 13.8 
2012 2264 16.4 
2013 1724 12.5 
2014 2190 15.9 
2015 2798 20.3 
2016 1230 8.9 
Validated biospecimen?  7572/13609 55.6 
Biospecimen site/type Cervical Swab 1012 7.4 
Endocervical 10 0.1 
Eye 11 0.1 
High vaginal 
swab 
39 0.3 
Lower vaginal 
swab 
73 0.5 
Rectal 2427 17.8 
Throat 3599 26.4 
Unknown 194 1.4 
Urethral Swab 286 2.1 
Urine 4285 31.5 
Vaginal Swab 
(not defined) 
322 2.4 
Vulval Swab 1545 11.4 
Senders/screening Assay Abbott RealTime CT/NG assay1 
10,139 73.5 
 
Roche Cobas 
4800 CT/NG2 
1824 13.2 
 
BD ProbeTec™ 
ET GC3 
1841 13.3 
Table 1: Key characteristics/variables of 13803 samples, received for Neisseria gonorrhoeae 
confirmatory testing included in the analysis.   
1: https://www.molecular.abbott/sal/en-us/staticAssets/ctng-8l07-91-us final.pdf 
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2:https://pimeservices.roche.com/eLD_SF/gb/en/Documents/GetDocument?documentId=4d186450-4bf2-
e811-edbb-00215a9b3428.  
3:http://moleculardiagnostics.bd.com/syndromic-solutions/womens-health-stis/ct-gc-tv 
 
 
Screening 
Assay 
Number 
confirmation 
test positive 
Number 
positive by 
assay 
% confirmed by 
reference test (95% 
CI) 
Abbott 
RealTime 
CT/NG  
9439 10139 93.1 (92.6 – 93.6) 
Roche 
Cobas 
4800 
CT/NG 
1532 1824 84.0 (82.2 – 85.6) 
BD 
ProbeTec™ 
ET GC 
1214 1841 65.9 ( 63.7 – 68.1) 
All 12184 13803 88.3 ( 87.7 – 88.8) 
• Table 2: Overall confirmation according to screening assay
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Abbott RealTime CT/NG 
assay Roche Cobas 4800 CT/NG BD ProbeTec™ ET GC Overall 
Confirm
atory 
test 
positive 
n=9439 
% 
Confirm
atory 
test 
positive 
Abbo
tt 
positi
ve  
n=10
139 
Confirm
atory 
test 
positive 
n=1532 
% 
Confirm
atory 
test 
positive 
Roch
e 
posit
ive  
n=18
24 
Confirm
atory 
test 
positive 
n=1214 
% 
Confirm
atory 
test 
positive 
BD 
posit
ive  
n=18
41 
Confirm
atory 
test  
n=12184 
% 
Confirm
atory 
test 
positive 
All 
positi
ve by 
any 
assay 
n=13
803 
Sex Female 2819 93.6 3011 438 80.5 544 357 58.0 616 3614 86.6 4171 
Male 6605 92.9 7110 1093 85.5 1279 856 70.1 1221 8553 89.0 9609 
Unknown 15 83.3 18 1 100.0 1 1 25.0 4 17 73.9 23 
Sample year 2009 221 97.8 226 1 4.2 24 29 82.9 35 250 88.0 284 
2010 1143 96.1 1190 74 82.2 90 94 68.6 137 1311 92.5 1417 
2011 1462 97.3 1502 245 94.2 260 101 75.4 134 1808 95.4 1896 
2012 1726 96.2 1795 193 74.8 258 144 68.2 211 2063 91.1 2264 
2013 1162 93.8 1239 204 86.1 237 152 61.3 248 1518 88.1 1724 
2014 1372 91.2 1505 283 85.8 330 214 60.3 355 1869 85.3 2190 
2015 1579 87.9 1796 383 85.1 450 364 65.9 552 2326 83.1 2798 
2016 774 87.4 886 149 85.1 175 116 68.6 169 1039 84.5 1230 
Validated 
biospecimen? 
No 3757 89.1 4218 705 82.1 859 568 59.2 960 5030 83.3 6037 
Unknown 132 86.8 152 14 70.0 20 11 50.0 22 157 80.9 194 
Yes 5550 96.2 5769 813 86.0 945 635 73.9 859 6997 92.4 7572 
Biospecimen 
site/type 
Cervical 
Swab 
729 96.2 758 105 76.1 138 68 58.6 116 902 89.1 1012 
Endocervi
cal 
5 83.3 6 3 100.0 3 0 0.0 1 8 80.0 10 
Eye 4 100.0 4 0 0.0 1 2 33.3 6 6 54.5 11 
High 
vaginal 
21 95.5 22 8 80.0 10 5 71.4 7 34 87.2 39 
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swab 
Lower 
vaginal 
swab 
29 87.9 33 11 78.6 14 13 50.0 26 53 72.6 73 
Rectal 1727 91.5 1887 264 90.1 293 216 87.4 247 2207 90.9 2427 
Throat 2026 87.1 2327 441 78.1 565 350 49.5 707 2817 78.3 3599 
Unknown 132 86.8 152 14 70.0 20 11 50.0 22 157 80.9 194 
Urethral 
Swab 
196 99.0 198 21 84.0 25 61 96.8 63 278 97.2 286 
Urine 3328 97.7 3405 486 89.5 543 281 83.1 338 4094 95.5 4285 
Vaginal 
Swab 
267 92.4 289 19 95.0 20 8 61.5 13 294 91.3 322 
Vulval 
Swab 
975 92.2 1058 160 83.3 192 199 67.5 295 1334 86.3 1545 
Table 3: Confirmation stratified by screening assay, sex, year, validation status and anatomical site 
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Odds Ratio Estimates 
Assay Effect Point 
Estimate 
95% Wald 
Confidence 
Limit lower 
95% Wald 
Confidence 
Limit upper 
Abbott RealTime 
CT/NG assay  
Sex F vs M 1.955 1.398 2.733 
SAMPLE YEAR 0.747 0.713 0.782 
SAMPLE Cervical vs Vulval 1.579 1.023 2.437 
SAMPLE Rectal vs Vulval 1.843 1.225 2.774 
SAMPLE Throat vs Vulval 1.147 0.771 1.706 
SAMPLE Urethral vs Vulval 15.429 3.621 65.739 
SAMPLE Urine vs Vulval 7.423 4.707 11.708 
SAMPLE Vaginal vs Vulval 1.481 0.936 2.344 
Roche Cobas 4800 
CT/NG 
Sex F vs M 0.901 0.580 1.401 
SAMPYEAR 1.101 1.024 1.185 
SAMPLE Cervical vs Vulval 0.742 0.426 1.290 
SAMPLE Rectal vs Vulval 1.584 0.812 3.090 
SAMPLE Throat vs Vulval 0.633 0.361 1.111 
SAMPLE Urethral vs Vulval 0.915 0.271 3.093 
SAMPLE Urine vs Vulval 1.610 0.862 3.006 
SAMPLE Vaginal vs Vulval 1.292 0.503 3.315 
BD ProbeTec™ ET GC  Sex F vs M 0.458 0.315 0.664 
SAMPLE YEAR 0.927 0.872 0.984 
Genital_validated N vs Y 0.247 0.161 0.377 
SAMPLE Cervical vs Vulval 0.604 0.385 0.947 
SAMPLE Rectal vs Vulval 6.594 4.385 9.915 
SAMPLE Urethral vs Vulval 6.130 1.396 26.914 
SAMPLE Urine vs Vulval 1.125 0.674 1.877 
SAMPLE Vaginal vs Vulval 0.630 0.335 1.187 
Table 4:  Summary of logistic regression models by assay showing variables identified as 
associated with NG confirmation.  
 
 
 
 
 
 
 
17 
 
References  
1. Cullen BL, Wallace LA, Glancy ME, Shepherd J, Templeton K, Goldberg DJ. 2018. 
Health Protection Scotland surveillance report: genital chlamydia and gonorrhoea 
infection in Scotland: laboratory diagnoses 2008-17. Available from 
https://www.hps.scot.nhs.uk/resourcedocument.aspx?id=6721 
 
2. Public Health England. Sexually transmitted infections and Chlamydia screening in 
England, 2017. Available from 
https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attac
hment_data/file/713944/hpr2018_AA-STIs_v5.pdf 
 
3. Bennett A, Jeffery K, O'Neill E, Sherrard J. Outbreak or illusion: consequences of 
'improved' diagnostics for gonorrhoea. 2017. Int J STD AIDS.28(7):667-671.  
 
4. Vyth R, Leval A, Eriksson B, Ericson EL, Marions L, Hergens MP. 2016. Gonorrhoea 
Diagnostic and Treatment Uncertainties: Risk Factors for Culture Negative 
Confirmation after Positive Nucleic Acid Amplification Tests. PLoS One. 
6;11(5):e0155017.  
 
5. Public Health England. 2018. Guidance for the detection of gonorrhoea in England. 
2014. Available at: 
https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attac
hment_data/file/405293/170215_Gonorrhoea_testing_guidance_REVISED__2_.pdf 
[Accessed 13 Aug. 2018]. 
 
6. UK national guideline for the management of gonorrhoea in adults (2011). BASHH. 
UK national. Available at: https://www.bashhguidelines.org/media/1044/gc-
2011.pdf [Accessed 13 Aug. 2018]. 
 
7. CDC.gov Laboratory Recommendations | CDC. [online] Available at: 
https://www.cdc.gov/std/laboratory/2014labrec/default.htm [Accessed 13 Aug. 
2018]. 
 
8.  Scottish Microbiology Forum, British Association for Sexual Health and HIV, and 
Health Protection Scotland. Guidance on the user of molecular testing for Neisseria 
 
 
18 
 
gonorrhoeae in diagnostic laboratories 2011. Molecular testing for gonorrhoea 
working group, Edinburgh, Scottish Bacterial Sexually Transmitted Infections 
Laboratory. 2012. Available from 
https://www.hps.scot.nhs.uk/resourcedocument.aspx?resourceid=190 
 
9. Whiley & Sloots 2005  Comparison of three in-house multiplex PCR assays for the detection 
of Neisseria gonorrhoeae and Chlamydia trachomatis using real-time and conventional 
detection methodologies.  Pathology 37(5):364-370 
 
 
10. Hopkins MJ, Smith G, Hart IJ, Alloba F. 2012. Screening tests for Chlamydia 
trachomatis or Neisseria gonorrhoeae using the cobas 4800 PCR system do not 
require a second test to confirm: an audit of patients issued with equivocal results at 
a sexual health clinic in the Northwest of England, U.K. Sex Transm Infect. 88(7):495-
7.  
 
11. Schachter J, Chernesky MA. Routine confirmation of positive nucleic acid 
amplification test results for Neisseria gonorrhoeae is not necessary. J Clin Microbiol. 
2012 Jan;50(1):208; author reply 209-10. doi: 10.1128/JCM.06004-11. PubMed 
PMID: 22203751; PubMed Central PMCID: PMC3256691 
 
12. Perry MD, Jones RN, Corden SA. 2014. Is confirmatory testing of Roche cobas 4800 
CT/NG test Neisseria gonorrhoeae positive samples required? Comparison of the 
Roche cobas 4800 CT/NG test with an opa/pap duplex assay for the detection of N 
gonorrhoeae. Sex Transm Infect. 90(4):303-8.  
 
13. Causer LM, Guy RJ, Tabrizi SN, Whiley DM, Speers DJ, Ward J, Tangey A, Badman SG, 
Hengel B, Natoli LJ, Anderson DA, Wand H, Wilson D, Regan DG, Shephard M, 
Donovan B, Fairley CK, Kaldor JM. 2018. Molecular test for chlamydia and 
gonorrhoea used at point of care in remote primary healthcare settings: a diagnostic 
test evaluation. Sex Transm Infect. 94(5):340-345. 
 
14. Badman SG, Causer LM, Guy R, Wand H, Donovan B, Tabrizi SN, Speers D, Shephard 
MD, Vallely A, Whiley D; TTANGO investigators. 2018. A reliable and easy to 
transport quality control method for chlamydia and gonorrhoea molecular point of 
care testing. Pathology. 50(3):317-321.  
 
15. Horst AL, Rosenbohm JM, Kolluri N, Hardick J, Gaydos CA, Cabodi M, Klapperich  CM, 
Linnes JC. 2018. A paperfluidic platform to detect Neisseria gonorrhoeae in clinical 
samples. Biomed Microdevices. 11;20(2):35.  
 
 
19 
 
 
16. Speers DJ, Chua IJ, Manuel J, Marshall L. Detection of Neisseria gonorrhoeae and 
Chlamydia trachomatis from pooled rectal, pharyngeal and urine specimens in men 
who have sex with men. 2018. Sex Transm Infect. 94(4):293-297 
 
 
 
